{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:54Z","timestamp":1792788474636,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","award":["CIFMS 2023-I2M-3-012"],"award-info":[{"award-number":["CIFMS 2023-I2M-3-012"]}],"id":[{"id":"https:\/\/ror.org\/02drdmm93","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National High Level Hospital Clinical Research Funding","award":["2023-PUMCH-E-006"],"award-info":[{"award-number":["2023-PUMCH-E-006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1245\/s10434-026-20322-y","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:41:40Z","timestamp":1786038100000},"page":"10690-10702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Dongfeng","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"10251","key":"20322_CR1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet (Lond, Engl). 2020;396(10251):635\u201348.","journal-title":"Lancet (Lond, Engl)"},{"issue":"16","key":"20322_CR2","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"20322_CR3","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197\u2013203.","journal-title":"JAMA Oncol"},{"issue":"13","key":"20322_CR4","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, Conroy T, Bouch\u00e9 O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10184","key":"20322_CR5","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet (Lond, Engl). 2019;393(10184):1948\u201357.","journal-title":"Lancet (Lond, Engl)"},{"issue":"8","key":"20322_CR6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 2021;22(8):1081\u201392.","journal-title":"Lancet Oncol"},{"issue":"26","key":"20322_CR7","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.20.02914","volume":"39","author":"YK Kang","year":"2021","unstructured":"Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol. 2021;39(26):2903\u201313.","journal-title":"J Clin Oncol"},{"issue":"6","key":"20322_CR8","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ijc.33696","volume":"149","author":"RD Hofheinz","year":"2021","unstructured":"Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer. 2021;149(6):1322\u201331.","journal-title":"Int J Cancer"},{"issue":"32","key":"20322_CR9","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, et al. FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40(32):3750\u201361.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"20322_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1186\/s12885-019-5675-4","volume":"19","author":"AD Wagner","year":"2019","unstructured":"Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, et al. EORTC-1203-GITCG - the \u201cINNOVATION\u201d-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC cancer. 2019;19(1):494.","journal-title":"BMC cancer"},{"issue":"8","key":"20322_CR11","doi-asserted-by":"crossref","first-page":"e29485","DOI":"10.1016\/j.heliyon.2024.e29485","volume":"10","author":"J Wang","year":"2024","unstructured":"Wang J, Xu G, Liu S, Ma Y, Wang S, Li M, et al. Evaluation of the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant and conversion therapy for advanced gastric cancer: a study protocol of prospective single-center, randomized controlled and open label clinical trial (RNPLS-01). Heliyon. 2024;10(8):e29485.","journal-title":"Heliyon"},{"issue":"9","key":"20322_CR12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/fon-2018-0581","volume":"15","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol (Lond, Engl). 2019;15(9):943\u201352.","journal-title":"Future Oncol (Lond, Engl)"},{"issue":"20","key":"20322_CR13","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.2217\/fon-2022-0093","volume":"18","author":"YY Janjigian","year":"2022","unstructured":"Janjigian YY, Van Cutsem E, Muro K, Wainberg Z, Al-Batran SE, Hyung WJ, et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric\/gastroesophageal junction cancer. Future Oncol (Lond, Engl). 2022;18(20):2465\u201373.","journal-title":"Future Oncol (Lond, Engl)"},{"key":"20322_CR14","doi-asserted-by":"crossref","unstructured":"Li C, Tian Y, Zheng Y, Yuan F, Shi Z, Yang L, et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J Clin Oncol Off J Am Soc Clin Oncol 2024:Jco2400795.","DOI":"10.1200\/JCO.24.00795"},{"issue":"6","key":"20322_CR15","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/07357907.2014.911877","volume":"32","author":"BH Xiong","year":"2014","unstructured":"Xiong BH, Cheng Y, Ma L, Zhang CQ. An updated meta-analysis of randomized controlled trial assessing the effect of neoadjuvant chemotherapy in advanced gastric cancer. Cancer Invest. 2014;32(6):272\u201384.","journal-title":"Cancer Invest"},{"issue":"12","key":"20322_CR16","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S1470-2045(16)30531-9","volume":"17","author":"SE Al-Batran","year":"2016","unstructured":"Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708.","journal-title":"Lancet Oncol"},{"issue":"6","key":"20322_CR17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1200\/JCO.2005.01.305","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(6):1237\u201344.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"20322_CR18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.21037\/tcr.2019.11.37","volume":"9","author":"T Wang","year":"2020","unstructured":"Wang T, Wang N, Zhou H, Zhou A, Jin J, Chen Y, et al. Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection. Transl Cancer Res. 2020;9(2):529\u201335.","journal-title":"Transl Cancer Res"},{"issue":"12","key":"20322_CR19","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1038\/bjc.2011.175","volume":"104","author":"RC Fields","year":"2011","unstructured":"Fields RC, Strong VE, G\u00f6nen M, Goodman KA, Rizk NP, Kelsen DP, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer. 2011;104(12):1840\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"20322_CR20","doi-asserted-by":"crossref","first-page":"e0189294","DOI":"10.1371\/journal.pone.0189294","volume":"13","author":"Z Li","year":"2018","unstructured":"Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis. PloS One. 2018;13(1):e0189294.","journal-title":"PloS One"},{"issue":"3","key":"20322_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s00280-019-03893-4","volume":"84","author":"X Xu","year":"2019","unstructured":"Xu X, Zheng G, Zhang T, Zhao Y, Zheng Z. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Cancer Chemother Pharmacol. 2019;84(3):635\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"20322_CR22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.21037\/atm.2019.09.82","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang X, Li X, Zhou N, Zhong D, Bai C, Zhao L. Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Ann Transl Med. 2019;7(20):546.","journal-title":"Ann Transl Med"},{"issue":"1","key":"20322_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00423-024-03388-8","volume":"409","author":"F Abboretti","year":"2024","unstructured":"Abboretti F, Mantziari S, Didisheim L, Sch\u00e4fer M, Teixeira Farinha H. Prognostic value of tumor regression grade (TRG) after oncological gastrectomy for gastric cancer. Langenbecks Arch Surg. 2024;409(1):199.","journal-title":"Langenbecks Arch Surg"},{"issue":"2","key":"20322_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4143\/crt.2023.812","volume":"56","author":"L Mineur","year":"2024","unstructured":"Mineur L, Plat F, Desseigne F, Deplanque G, Belkacemi M, Moureau-Zabotto L, et al. NESC multicenter phase II trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU+lenograstim) followed by chemoradiation based 5FU and oxaliplatin and surgery. Cancer Res Treat. 2024;56(2):580\u20139.","journal-title":"Cancer Res Treat"},{"key":"20322_CR25","doi-asserted-by":"crossref","first-page":"1440046","DOI":"10.3389\/fonc.2024.1440046","volume":"14","author":"H Mechahougui","year":"2024","unstructured":"Mechahougui H, Chevallay M, Cauchy F, Chaveau N, Puppa G, Koessler T, et al. Complete response of a metastatic microsatellite-stable gastric cancer after neoadjuvant chemoimmunotherapy: should we still operate? A case report and review of the literature. Front Oncol. 2024;14:1440046.","journal-title":"Front Oncol"},{"issue":"6","key":"20322_CR26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4251\/wjgo.v15.i6.1096","volume":"15","author":"ML Zhou","year":"2023","unstructured":"Zhou ML, Xu RN, Tan C, Zhang Z, Wan JF. Advanced gastric cancer achieving major pathologic regression after chemoimmunotherapy combined with hypofractionated radiotherapy: A case report. World J Gastrointest Oncol. 2023;15(6):1096\u2013104.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"20322_CR27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/wjs.12482","volume":"49","author":"H Nagata","year":"2025","unstructured":"Nagata H, Kinoshita T, Sakashita S, Kojima M, Taki T, Kuwata T, et al. Area of residual tumor measurement after preoperative chemotherapy as an objective and quantitative method for predicting the prognosis of gastric cancer: a single-center retrospective study. World J Surg. 2025;49(3):717\u201326.","journal-title":"World J Surg"},{"key":"20322_CR28","doi-asserted-by":"crossref","first-page":"108895","DOI":"10.1016\/j.cmpb.2025.108895","volume":"269","author":"L Liu","year":"2025","unstructured":"Liu L, Zhang Y, Zhao XH, Zhu M, Liang JW, Jiang ZY, et al. Predicting clinical prognosis in gastric cancer using deep learning-based analysis of tissue pathomics images. Comput Methods Programs Biomed. 2025;269:108895.","journal-title":"Comput Methods Programs Biomed"},{"issue":"12","key":"20322_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/bjc.2016.126","volume":"114","author":"X Wang","year":"2016","unstructured":"Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114(12):1326\u201333.","journal-title":"Br J Cancer"},{"issue":"12","key":"20322_CR30","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1245\/s10434-007-9574-6","volume":"14","author":"JC Mansour","year":"2007","unstructured":"Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, et al. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surgical Oncol. 2007;14(12):3412\u20138.","journal-title":"Ann Surgical Oncol"},{"issue":"5","key":"20322_CR31","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/jclinpath-2017-204774","volume":"71","author":"C Hedner","year":"2018","unstructured":"Hedner C, Borg D, Nodin B, Karnevi E, Jirstr\u00f6m K, Eberhard J. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. J Clin Pathol. 2018;71(5):451\u201362.","journal-title":"J Clin Pathol"},{"issue":"1","key":"20322_CR32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90\u20132.","journal-title":"Actas Dermosifiliogr"},{"issue":"1","key":"20322_CR33","doi-asserted-by":"publisher","first-page":"15150","DOI":"10.1038\/s41598-024-65724-8","volume":"14","author":"N Li","year":"2024","unstructured":"Li N, Wu H, Xu X, Wei Q, Ding Y, Liu S, et al. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer. Sci Rep. 2024;14(1):15150.","journal-title":"Sci Rep"},{"issue":"1","key":"20322_CR34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12957-025-03723-3","volume":"23","author":"FY Wang","year":"2025","unstructured":"Wang FY, Huang XM, Cao YQ, Cao J, Song M, Fang ZJ, et al. Comparison of PSOX (paclitaxel, oxaliplatin, S-1) and SOX (oxaliplatin, S-1) as postoperative adjuvant chemotherapy for stage II-III gastric cancer. World J Surg Oncol. 2025;23(1):75.","journal-title":"World J Surg Oncol"},{"key":"20322_CR35","doi-asserted-by":"crossref","unstructured":"Cheng X, Wu D, Xu N, Chen L, Yan Z, Chen P, et al. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC Cancer 2021; 21(1):56.","DOI":"10.1186\/s12885-020-07772-7"},{"issue":"4","key":"20322_CR36","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/path.6400","volume":"265","author":"K Harada","year":"2025","unstructured":"Harada K, Sakamoto N, Kitaoka T, Nakamura Y, Kondo R, Morisue R, et al. PI3 expression predicts recurrence after chemotherapy with DNA-damaging drugs in gastric cancer. J Pathol. 2025;265(4):472\u201385.","journal-title":"J Pathol"},{"issue":"5\u20136","key":"20322_CR37","first-page":"835","volume":"29","author":"SQ Li","year":"2024","unstructured":"Li SQ, Xu WT, Yin YX, Wei HT, Li KZ, Xie MZ, et al. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis. Apoptosis Int J Programmed Cell Death. 2024;29(5\u20136):835\u201348.","journal-title":"Apoptosis Int J Programmed Cell Death"},{"issue":"13","key":"20322_CR38","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-24-4190","volume":"85","author":"B Qiu","year":"2025","unstructured":"Qiu B, Zheng Y, Liu S, Song R, Wu L, Lu C, et al. Multitask Deep learning based on longitudinal CT images facilitates prediction of lymph node metastasis and survival in chemotherapy-treated gastric cancer. Cancer Res. 2025;85(13):2527\u201336.","journal-title":"Cancer Res"},{"issue":"8","key":"20322_CR39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/RLI.0000000000001064","volume":"59","author":"M Graf","year":"2024","unstructured":"Graf M, Gawlitza J, Makowski M, Meurer F, Huber T, Ziegelmayer S. Evaluating treatment response in GEJ adenocarcinoma: the role of pretherapeutic and posttherapeutic iodine mapping. Invest Radiol. 2024;59(8):583\u20138.","journal-title":"Invest Radiol"},{"key":"20322_CR40","doi-asserted-by":"crossref","unstructured":"Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, et al. Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. J Immunother Cancer 2022","DOI":"10.1136\/jitc-2021-003635"},{"issue":"4","key":"20322_CR41","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","volume":"30","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, et al. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses. Nat Med. 2024;30(4):1023\u201334.","journal-title":"Nat Med"},{"issue":"12","key":"20322_CR42","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1097\/JS9.0000000000000692","volume":"109","author":"Y Tian","year":"2023","unstructured":"Tian Y, Yang P, Guo H, Liu Y, Zhang Z, Ding P, et al. Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial. Int J Surg (Lond, Engl). 2023;109(12):4000\u20138.","journal-title":"Int J Surg (Lond, Engl)"},{"issue":"4","key":"20322_CR43","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1097\/JS9.0000000000001119","volume":"110","author":"N Li","year":"2024","unstructured":"Li N, Li Z, Fu Q, Zhang B, Zhang J, Wan XB, et al. Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study. Int J Surg (Lond, Engl). 2024;110(4):2071\u201384.","journal-title":"Int J Surg (Lond, Engl)"},{"issue":"12","key":"20322_CR44","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jamaoncol.2023.4423","volume":"9","author":"GA Manji","year":"2023","unstructured":"Manji GA, Lee S, Del Portillo A, May M, Ana SS, Alouani E, et al. Chemotherapy and immune checkpoint blockade for gastric and gastroesophageal junction adenocarcinoma. JAMA Oncol. 2023;9(12):1702\u20137.","journal-title":"JAMA Oncol"},{"issue":"2","key":"20322_CR45","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol"},{"key":"20322_CR46","first-page":"S879","volume":"35","author":"DS Liu","year":"2024","unstructured":"Liu DS, Hall K, Wong D, Lee MMW, Duong C, Bright T, et al. 1402MO An international study evaluating pathological response to guide adjuvant FLOT chemotherapy in gastroesophageal cancer. Ann Oncol. 2024;35:S879.","journal-title":"Ann Oncol"},{"issue":"12","key":"20322_CR47","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.2004.05.207","volume":"22","author":"E Thomas","year":"2004","unstructured":"Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(12):2294\u2013302.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"22","key":"20322_CR48","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"20322_CR49","doi-asserted-by":"crossref","first-page":"185","DOI":"10.21873\/anticanres.16801","volume":"44","author":"T Sugase","year":"2024","unstructured":"Sugase T, Kanemura T, Takeoka T, Matsuura N, Masuike Y, Shinno N, et al. Short-term outcomes of adjuvant nivolumab after neoadjuvant chemotherapy in patients with resected esophageal squamous cell carcinoma. Anticancer Res. 2024;44(1):185\u201393.","journal-title":"Anticancer Res"},{"issue":"1","key":"20322_CR50","doi-asserted-by":"crossref","first-page":"391","DOI":"10.21037\/jtd-23-1484","volume":"16","author":"T Chinen","year":"2024","unstructured":"Chinen T, Yamaguchi H, Ohzawa H, Matsumoto S, Kurashina K, Saito S, et al. Equivalent prognosis with no lymph node metastasis to pathological complete remission in patients with localized advanced esophageal cancer after neoadjuvant triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by curative surgery: a single-center retrospective cohort study. J Thorac Dis. 2024;16(1):391\u2013400.","journal-title":"J Thorac Dis"},{"issue":"13","key":"20322_CR51","doi-asserted-by":"publisher","first-page":"8892","DOI":"10.1245\/s10434-021-10087-x","volume":"28","author":"Z Liu","year":"2021","unstructured":"Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, et al. Treatment switch in poor responders with locally advanced gastric cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2021;28(13):8892\u2013907.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"20322_CR52","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","volume":"17","author":"NM Marina","year":"2016","unstructured":"Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016;17(10):1396\u2013408.","journal-title":"Lancet Oncol"},{"issue":"3","key":"20322_CR53","first-page":"465","volume":"28","author":"CM Weng","year":"2025","unstructured":"Weng CM, Zhong Q, Sun YQ, Liu ZY, Ma YB, Zhang ZQ, et al. A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2025;28(3):465\u201377.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"4","key":"20322_CR54","first-page":"1463","volume":"11","author":"X Zheng","year":"2021","unstructured":"Zheng X, Guo K, Wasan HS, Ruan S. A population-based study: how to identify high-risk T1 gastric cancer patients? Am J Cancer Res. 2021;11(4):1463\u201379.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"20322_CR55","first-page":"752","volume":"24","author":"A Yago","year":"2021","unstructured":"Yago A, Haruta S, Ueno M, Hamada Y, Ogawa Y, Ohkura Y, et al. Adequate period of surveillance in each stage for curatively resected gastric cancer: analyzing the time and rates of recurrence. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2021;24(3):752\u201361.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"issue":"5","key":"20322_CR56","first-page":"734","volume":"26","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Ren Y, Zhang Z, Guan T, Wang Z, Chen W, et al. Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2023;26(5):734\u201342.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20322-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20322-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:23:08Z","timestamp":1792207388000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20322-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20322"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20322-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study complies with the ethical guidelines and legal requirements of China, as well as the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was registered with ClinicalTrials.gov, NCT03322969. All participants provided written informed consent prior to participation.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have consented to the publication of the relevant content.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}